Amivantamab Intravenous
Phase 3
Johnson & JohnsonAmivantamab Intravenous is one of 5 therapeutic programs targeting Advanced or Metastatic Non-small Cell Lung Cancer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
5 competitors in Advanced or Metastatic Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Lazcluze
Johnson & JohnsonPhase 3
Imfinzi
AstraZenecaPhase 3
Taxotere
AAvyxa
Phase 3
Ceralasertib
AstraZenecaPhase 3
Amivantamab Intravenous
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced or Metastatic Non-small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Amivantamab Intravenous. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company